HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NBTY Forced To Hike Prices By Leiner Integration Costs, Shrinking Margins

This article was originally published in The Tan Sheet

Executive Summary

NBTY plans to raise prices for its Nature's Bounty brand dietary supplements in January 2009 following a 63.8 percent decrease in net income in its latest earnings period

You may also be interested in...

NBTY Expects Potholes On Private Label Profit Road

Dietary supplement manufacturer and retailer NBTY expects increased competition in the store brand arena to drive down its gross profits, nearly two years after it made private label sales a much larger part of its business by acquiring competitor Leiner Health Products

NBTY Cites Lower Margins As The Cost Of Higher Private-Label Sales

Dietary supplement manufacturer NBTY's gross margins are unlikely to exceed 50 percent again largely because private-label product sales have nearly doubled since its acquisition of Leiner Health Products

Sales & Earnings In Brief

Chattem expects another "very good year": Chattem prepares to roll out at least six new products in 2009 and is "at a tipping point on moving to the next level," the Chattanooga, Tenn.-based company says. CEO and Chairman Zan Guerry explained during a Jan. 29 fourth-quarter earnings call that the firm has "the best new products line-up, the highest scoring advertising on the biggest promotions kicking off in February through June in history," making 2009 likely another strong year. In fiscal 2008, the firm's total revenues grew 7.4 percent to $454.9 million fueled primarily by the addition of brands acquired from Johnson & Johnson. The company's oral care category advanced 29 percent to $62.9 million and internal OTCs were up 7 percent to $48 million in the September-November period. Chattem's net income grew 11 percent to $66.3 million

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts